Azenta, Inc. (NASDAQ:AZTA) Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC increased its position in Azenta, Inc. (NASDAQ:AZTA) by 1.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,317,385 shares of the company’s stock after acquiring an additional 18,529 shares during the period. Allspring Global Investments Holdings LLC owned approximately 2.88% of Azenta worth $65,922,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of AZTA. Sanctuary Advisors LLC acquired a new position in Azenta during the 2nd quarter valued at about $222,000. Procyon Advisors LLC acquired a new position in Azenta during the 3rd quarter valued at about $247,000. Net Worth Advisory Group acquired a new position in Azenta during the 3rd quarter valued at about $205,000. Nisa Investment Advisors LLC increased its stake in Azenta by 1.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 36,710 shares of the company’s stock valued at $1,778,000 after buying an additional 700 shares during the period. Finally, Farther Finance Advisors LLC increased its stake in Azenta by 20.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock valued at $74,000 after buying an additional 256 shares during the period. Institutional investors and hedge funds own 99.08% of the company’s stock.

Insiders Place Their Bets

In related news, CEO John Marotta purchased 12,717 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was acquired at an average cost of $39.48 per share, for a total transaction of $502,067.16. Following the completion of the acquisition, the chief executive officer now owns 99,612 shares in the company, valued at $3,932,681.76. This trade represents a 14.63 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William L. Cornog bought 12,500 shares of Azenta stock in a transaction on Monday, November 18th. The stock was acquired at an average price of $39.60 per share, with a total value of $495,000.00. Following the completion of the purchase, the director now directly owns 14,755 shares of the company’s stock, valued at approximately $584,298. The trade was a 554.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 1,423 shares of company stock worth $57,020 over the last ninety days. 10.62% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have commented on AZTA shares. Needham & Company LLC raised their target price on shares of Azenta from $55.00 to $59.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Evercore ISI raised their target price on shares of Azenta from $50.00 to $52.00 and gave the company an “in-line” rating in a research note on Thursday, February 6th. Finally, Stephens reissued an “overweight” rating and set a $60.00 target price on shares of Azenta in a research note on Thursday, January 2nd.

Azenta Price Performance

Shares of AZTA opened at $45.10 on Friday. The firm’s 50 day moving average is $50.56 and its 200-day moving average is $48.71. The stock has a market capitalization of $2.06 billion, a P/E ratio of -15.13 and a beta of 1.47. Azenta, Inc. has a 12-month low of $38.82 and a 12-month high of $67.77.

Azenta (NASDAQ:AZTA) last announced its earnings results on Wednesday, February 5th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.05 by $0.03. Azenta had a negative net margin of 24.91% and a positive return on equity of 1.25%. As a group, equities research analysts forecast that Azenta, Inc. will post 0.42 EPS for the current fiscal year.

About Azenta

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.